edoc

Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis : a randomised, placebo-controlled, double-blind trial

Straumann, A. and Conus, S. and Grzonka, P. and Kita, H. and Kephart, G. and Bussmann, C. and Beglinger, C. and Smith, D. A. and Patel, J. and Byrne, M. and Simon, H.-U.. (2010) Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis : a randomised, placebo-controlled, double-blind trial. Gut, Vol. 59, H. 1. pp. 21-30.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6003952

Downloads: Statistics Overview

Abstract

Eosinophilic oesophagitis (EoO) is a clinicopathological condition defined by proton pump inhibitor-refractory oesophageal symptoms combined with oesophageal eosinophilia. The pharmacodynamic effect of mepolizumab (a humanised anti-interleukin-5 monoclonal antibody) in EoO was evaluated.
Faculties and Departments:03 Faculty of Medicine > Departement Biomedizin > Former Units at DBM > Gastroenterology (Beglinger)
UniBasel Contributors:Beglinger, Christoph
Item Type:Article, refereed
Article Subtype:Research Article
Bibsysno:Link to catalogue
Publisher:British Medical Association
ISSN:0017-5749
Note:Publication type according to Uni Basel Research Database: Journal article
Related URLs:
Identification Number:
Last Modified:08 Nov 2012 16:23
Deposited On:08 Nov 2012 16:18

Repository Staff Only: item control page